The following is a summary of “Effectiveness and safety of anti-CGRP monoclonal antibodies for migraine in patients over 65 ...

The people were followed for 2.9 years on average. The CDR is used globally to determine if a person has a form of dementia. The scale includes six domains; three are cognitive and three are ...

VUMC received up to $30M to develop AI for antibody therapy discovery, aiming to create an antibody-antigen atlas and ...

The global bispecific antibody (BsAb) market has witnessed significant growth, with 17 bispecific antibody therapies already ...

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

The first anti-amyloid monoclonal antibody -- and the first drug of any kind aimed at the Alzheimer's disease process -- gained FDA approval in June 2021: aducanumab (Aduhelm). However ...

VUMC has been awarded up to $30 million from the Advanced Research Projects Agency for Health (ARPA-H) to build a massive ...

Bispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...

Therapeutic antibodies are used to treat a wide range of diseases ... antigen target is and have a good chance of generating a monoclonal antibody therapeutic against that target in a very ...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix ...

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...